SCHEMBL30862827

SCHEMBL30862827

CC(C)(C)OC(=O)N1CCN(c2c3n(c4nc(C5=CCOCC5)nn4c2=O)[C@@H](C(=O)O)CC3)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.37
▸ ABCB1 P08183 1/20 0.34
▸ ABCG2 Q9UNQ0 1/20 0.34
▸ ADORA2A P29274 3/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ OPRM1 P35372 1/20 0.33
▸ OPRD1 P41143 1/20 0.33
▸ OGFRL1 Q5TC84 1/20 0.33
▸ TBK1 Q9UHD2 1/20 0.32
▸ DDB1 Q16531 2/20 0.32
▸ CRBN Q96SW2 2/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32
▸ GBA1 P04062 2/20 0.32
▸ CKS1B P61024 1/20 0.31
▸ SKP1 P63208 1/20 0.31
▸ SKP2 Q13309 1/20 0.31
▸ PIK3CA P42336 3/20 0.31
▸ GPR119 Q8TDV5 3/20 0.31
▸ MTOR P42345 1/20 0.31
▸ PIK3CG P48736 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30862765 0.92 WRN (0.40) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL30862825 0.88 WRN (0.36) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL30862758 0.86 WRN (0.44) WRNDDB1CRBNPIK3CAMTOR
SCHEMBL30862692 0.86 WRN (0.44) WRNDDB1CRBNPIK3CAMTOR
SCHEMBL30862712 0.84 WRN (0.48) WRNTBK1PIK3CAMTOR
SCHEMBL30862744 0.84 WRN (0.48) WRNTBK1PIK3CAMTOR
SCHEMBL30862808 0.81 OPRM1 (0.38) ABCB1ABCG2OPRM1OPRD1OGFRL1
SCHEMBL25036834 0.80 WRN (0.43) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL25037372 0.79 WRN (0.51) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL25037368 0.79 WRN (0.43) WRNABCB1ABCG2ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601746-A1 TRICYCLIC COMPOUNDS AND THEIR USES Novartis AG (CH) 2025-08-20 — — EP disclosed
CN-120077048-A Tricyclic compounds and uses thereof 诺华股份有限公司 2025-05-30 — — CN disclosed
US-20240245694-A1 Tricyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-07-25 — — US disclosed
WO-2024079623-A1 TRICYCLIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240245694-A1 Tricyclic Compounds and their Uses F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R WRN 2992/4885ABCB1 88/4885ABCG2 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback